Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME [Phase 2, Phase 3]

View source ↗

Summary

EyeBiotech is evaluating two doses of EYE103 against ranibizumab (0.5 mg) in participants with diabetic macular edema in a combined Phase 2/3 trial. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• EYE103
• Ranibizumab (ranibizumab)

Snippet

Sponsor: EyeBiotech Ltd. | Conditions: Diabetic Macular Edema (DME) | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING